TAMPA, Fla. — Lung cancer is the leading cause of cancer death among men and women. About 85 percent of lung cancers are non-small cell lung cancer. For a handful of these patients, therapies that target specific genetic mutations are effective. But for the majority of non-small cell lung cancer patients, targeted therapies are limited and many patients develop resistance to treatment, highlighting the need for other options.
Moffitt Cancer Center researchers are combining the large-scale study of proteins (proteomics) with a new data integration method to identify a previously unknown mechanism for midostaurin in lung cancer. Midostaurin is a drug approved by the United States Food and Drug Administration for the treatment of acute myeloid leukemia and advanced systemic mastocytosis. Their study was published in the journal Molecular & Cellular Proteomics.
The research team led by Uwe Rix, Ph.D., associate member of the Drug Discovery Department at Moffitt, worked to identify all of the proteins that interact with midostaurin in non-small cell lung cancer cells in the lab. They then used a data analysis technique developed in the Rix lab to further examine the pathways associated with those proteins. In the end, the researchers identified three protein targets
Article originally posted at